Gene Nexus

Gene Nexus aims to drive innovation in drug discovery through genetics- and OMICs-guided approaches and strategic planning, and provides consulting services in the following areas: 1. Bespoke target selection for emerging drug modalities 2. Genetics-driven novel target discovery and validation 3. Business development for CROs with genetics or biomedical intelligence based platforms pursuing pharma partnerships 4. Setting high-level scientific and commercial go-forward strategy for data-driven early R&D 5. Advancing diverse ancestry genomic biobanks with a focus on global health equity --- Founder and Principal Consultant: Sneha Grandhi, PhD Background: - 5 years at Pfizer's 'Emerging Science and Innovation' division, whose mission was to "Bring the Best of the Outside Into Pfizer" - Postdoctoral training at Harvard Medical School's Department of Genetics - PhD in Genetics and Genome Sciences (Case Western Reserve University) - B.S. in Genomics and Molecular Genetics, minor in Mathematics (Michigan State University) Achievements: - Led innovative projects using population genetics and OMICs data for novel target discovery - Proposed 8 first-in-class targets which entered Pfizer's discovery portfolio - Contributed to 4 successful stage gate transitions of Pfizer preclinical programs - Spearheaded 3 strategic partnerships with global biobanks and secured C-suite endorsement - Conducted pharma due diligence for 25+ biotechs, consortia, and AI/ML platforms seeking partnerships Expertise: - Disease-agnostic target discovery and validation (oncology, hematology, rare disease, inflammation, and CVD) - Diverse therapeutic modalities (small/large molecules, RNA tx, gene editing, heterobifunctional molecules / molecular glues) - Biomarker identification and patient population selection - Scientific communication and cross-functional collaboration